Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance

Citius Pharmaceuticals IncTrade
Direxion Daily FTSE China Bull 3x SharesTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Direxion Daily FTSE China Bull 3x Shares trades at $29.12. Which is the better fit depends on your goals.

CTXRYINN
Market Cap
$20.01M
Sector
HealthLeveraged / Inverse
52-Week High
$1.82$56.62
52-Week Low
$0.48$21.45
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Direxion Daily FTSE China Bull 3x Shares

YINN, a leveraged ETF tracking the FTSE China Bull 3x strategy, trades at $28.93, down 10.43% in 24 hours amid broad bearish technical signals. The fund lacks traditional financial ratios due to its structure, with a dividend of $0.21 scheduled for June 2026. Recent news highlights China's economic stimulus and AI investments, but geopolitical tensions and regulatory risks persist.

Outlook remains cautious due to leverage amplifying volatility; opportunities exist if Chinese equities rebound, but risks include US-China friction and economic slowdowns. Investors should weigh the ETF's high-risk profile against potential gains from China's tech growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Direxion Daily FTSE China Bull 3x Shares

YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.

Read more on YINN